Boehringer Ingelheim announces authorisation of Mirapexin/Sifrol

Boehringer Ingelheim has been notified of the European commission’s (EC) approval of its once-daily prolonged-release tablet therapy Mirapexin/Sifrol (pramipexole).

The drug has now been approved for all EU/EEA countries for the treatment of early and advanced idiopathic Parkinson’s disease – a decision based on the positive results of several clinical trials.

Doctor Manfred Haehl, senior vice-president of medicine at Boehringer Ingelheim, commented: “We are very pleased that due to the robust evidence base, the regulatory review experienced no delay, which will allow the first European countries to already make the once-daily tablet available to patients.”

Additionally, a new drug application for the treatment has also been submitted to the Food and Drug Administration.

In September, Boehringer Ingelheim announced the positive results of a trial into aggrenox (extended-release dipyridamole) – a drug for the treatment of both ischaemic strokes and transient ischaemic attacks.